11:11 AM EST, 11/04/2024 (MT Newswires) -- Enveric Biosciences ( ENVB ) said Monday that it secured five new patents and allowances for three more patent applications from the US Patent and Trademark Office for its EVM301 portfolio of molecules.

The company said its EVM301 portfolio now has nine patents, including the newly issued ones.

According to Enveric, EVM301's lead candidate EB-003 is under preclinical development to support an investigational new drug application in 2025. The company said EB-003 is being developed as a treatment for mental health disorders, including treatment-resistant depression and anxiety.

Shares of Enveric Biosciences ( ENVB ) were down more than 2% in recent trading.

Price: 0.48, Change: -0.01, Percent Change: -2.38